Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM AMINOSALICYLATE vs PASER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Exact mechanism unknown; may competitively inhibit folic acid synthesis and/or disrupt mycobacterial cell wall metabolism via inhibition of salicylate hydroxylation.
Inhibits cell wall synthesis in Mycobacterium tuberculosis by blocking mycolic acid synthesis. Also acts as a competitive inhibitor of folate synthesis.
Adjunctive treatment of tuberculosis (as second-line agent),Off-label: treatment of ulcerative colitis (as mesalamine prodrug)
Treatment of tuberculosis in combination with other antituberculosis drugs,Off-label: None
Adults: 4 g (as granules or powder) orally twice daily, equivalent to 8 g/day of aminosalicylic acid base.
4 g (8 capsules of 500 mg) orally every 8 hours, taken with food or an acidic beverage (e.g., orange juice) to enhance absorption.
0.5-1.5 hours for parent drug; acetylated metabolite half-life 2-3 hours; accumulation occurs in renal impairment.
Terminal elimination half-life is 1.5 to 2.5 hours in patients with normal renal function. In anuria or severe renal impairment (Cr Cl <10 m L/min), half-life may extend to 8-12 hours. Clinical context: Accumulation occurs with renal failure, requiring dose adjustment.
Hepatic (acetylation to N-acetyl-4-aminosalicylic acid and other metabolites); also undergoes intestinal metabolism by gut bacteria.
Hepatic via N-acetyltransferase (polymorphic acetylation); major metabolite is acetyl-PAS.
Renal: >80% as metabolites (acetyl, glycolyl conjugates) and unchanged drug; fecal: <5%.
Renal excretion accounts for approximately 80% of the administered dose, with about 60-70% as unchanged drug and 10-20% as metabolites (primarily acetylated). The remainder is excreted via feces (approximately 10-15%) and minor biliary elimination. Renal clearance is highly dependent on glomerular filtration rate.
50-60% bound to albumin.
Protein binding is approximately 10-15%, primarily to albumin. Binding is low, nonlinear, and saturable at high concentrations.
0.2-0.4 L/kg; reflects distribution into total body water with limited tissue penetration.
Volume of distribution is 0.5-0.7 L/kg, indicating distribution into total body water. Clinical meaning: Moderate distribution suggests penetration into well-perfused tissues but limited CNS penetration unless inflamed.
Oral: ~90% absorbed; food may delay absorption.
Oral bioavailability is approximately 70-80% (range 60-90%). Food decreases the rate and extent of absorption, with AUC reduction of about 20-40%.
GFR <50 m L/min: not recommended due to risk of accumulation; if unavoidable, reduce dose to 4 g once daily. GFR <30 m L/min: avoid use.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For Cr Cl 30-50 m L/min: reduce dose to 4 g orally every 12 hours; monitor serum concentrations. Use with caution in moderate impairment.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% (to 2 g twice daily). Child-Pugh Class C: avoid use.
No specific dose adjustment guidelines for Child-Pugh classification. Use with caution in severe hepatic impairment due to potential hepatotoxicity; monitor liver function tests.
Children: 200-300 mg aminosalicylic acid base per kg body weight per day, divided into 2 doses. Maximum 8 g/day.
Not recommended for children (safety and efficacy not established).
Start at lower end of dosing (4 g once daily) due to potential decreased renal function and increased risk of gastrointestinal intolerance.
Lower initial doses may be considered due to age-related decline in renal function. Monitor renal function and serum concentrations closely.
No FDA black box warning.
None
Hypersensitivity reactions including fever and rash,Hepatotoxicity (discontinue if jaundice or liver enzyme elevation occurs),Renal impairment may require dose adjustment,Gastrointestinal intolerance,May cause hypocalcemia and hypokalemia,Interference with thyroid function tests
May cause hypothyroidism, hepatitis, and crystalluria. Use with caution in patients with renal impairment or glucose-6-phosphate dehydrogenase deficiency.
Hypersensitivity to any salicylate component,Severe hepatic disease,Severe renal impairment (e GFR < 30 m L/min)
Hypersensitivity to para-aminosalicylic acid or any component; severe renal impairment.
Avoid alcohol. Take with food or milk to reduce gastrointestinal irritation. Avoid large amounts of high-potassium foods (e.g., bananas, oranges, potatoes) unless directed by a physician, as this drug may alter potassium levels. No specific food restrictions beyond these.
Take with food to reduce gastrointestinal irritation. Avoid high-fat meals as they may delay absorption. Avoid alcohol.
First trimester: Insufficient data; no known human teratogenicity but animal studies inconclusive. Second/third trimester: No documented fetal harm; use only if clearly needed.
PASER (aminosalicylic acid) is classified FDA pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity but some fetal toxicity at high doses. Second and third trimesters: No known major malformations; risks may include gastrointestinal intolerance in mother. Advised use only if clearly needed.
Excreted in breast milk; M/P ratio unknown. Caution due to potential for infant methemoglobinemia or gastrointestinal disturbances.
Excreted into breast milk in small amounts. M/P ratio unknown. Considered compatible with breastfeeding by American Academy of Pediatrics; monitor infant for diarrhea or rash.
No specific dose adjustment recommended; standard doses may be used, but monitor for potassium disturbances due to pregnancy-induced hypervolemia.
No dosing adjustment required for pregnancy. Pharmacokinetic changes in pregnancy (increased clearance) not significant for PASER; standard adult dose of 4 g twice daily is recommended.
Monitor for hepatotoxicity, including elevated liver enzymes and bilirubin, especially in the first 3 months of therapy. Administer with food to reduce GI upset. Concurrent use with rifampin may decrease rifampin levels; separate doses by 8-12 hours. Contraindicated in severe renal impairment (Cr Cl < 30 m L/min) due to risk of hypokalemia and salicylate toxicity. Hypersensitivity reactions including fever, rash, and eosinophilia may occur; discontinue if severe.
PASER (aminosalicylic acid) is a second-line antitubercular agent that inhibits folic acid synthesis. Administer with food to reduce GI upset; avoid concurrent use with salicylates due to additive GI irritation. Monitor for hepatotoxicity and hypersensitivity reactions. Drug levels should be monitored in patients with renal impairment.
Take this medication with food or milk to prevent stomach upset.,Do not take antacids containing aluminum or magnesium within 3 hours of this medication.,Avoid alcohol while taking this medication due to increased risk of liver damage.,Report any signs of liver problems (yellowing skin or eyes, dark urine, abdominal pain) to your doctor immediately.,Use effective contraception during treatment as this drug may harm an unborn baby.,Do not stop taking this medication without consulting your doctor, even if you feel better.,Keep all appointments for blood tests to monitor liver function and potassium levels.
Take this medication with food to minimize stomach upset.,Do not crush or chew the tablets; swallow them whole.,Complete the full course of therapy even if you feel better.,Report any signs of liver problems (yellowing of skin/eyes, dark urine) or allergic reactions (rash, fever) immediately.,Avoid alcohol during treatment.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM AMINOSALICYLATE vs PASER, answered by our medical review team.
POTASSIUM AMINOSALICYLATE is a Antitubercular Agent that works by Exact mechanism unknown; may competitively inhibit folic acid synthesis and/or disrupt mycobacterial cell wall metabolism via inhibition of salicylate hydroxylation.. PASER is a Antitubercular Agent that works by Inhibits cell wall synthesis in Mycobacterium tuberculosis by blocking mycolic acid synthesis. Also acts as a competitive inhibitor of folate synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM AMINOSALICYLATE and PASER depend on the specific clinical indication. These are both Antitubercular Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM AMINOSALICYLATE is: Adults: 4 g (as granules or powder) orally twice daily, equivalent to 8 g/day of aminosalicylic acid base.. The standard adult dose of PASER is: 4 g (8 capsules of 500 mg) orally every 8 hours, taken with food or an acidic beverage (e.g., orange juice) to enhance absorption.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM AMINOSALICYLATE and PASER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM AMINOSALICYLATE is classified as Category C. First trimester: Insufficient data; no known human teratogenicity but animal studies inconclusive. Second/third trimester: No documented fetal harm; use only if clearly needed.. PASER is classified as Category C. PASER (aminosalicylic acid) is classified FDA pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity but some fetal toxicity at high doses. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.